Because of the significant difference in expression levels between normal and tumor cells, erb-B2 has become an ideal target for tumor immunobiotherapy and is currently a hot molecule in the field of tumor therapy research (Mcdonagh et al., 2012). Here, ERBB2 is linked to neoplasm.